Urology Practice Management Considerations & Treatment Selection for Special Populations with Metastatic CRPC
Christopher M. Pieczonka, MD and Jose De La Cerda, MD, MPH engage in a comprehensive discussion on the nuances of abiraterone formulations for treating metastatic castration-resistant prostate cancer (mCRPC). They explore patient assessment, treatment considerations for special populations, and clinical practice management tailored to the diverse needs of patients with mCRPC.
The Evolving Role of IRP Monitoring in the Treatment and Management of Urinary Stones
Michelle Semins, MD, and Seth Bechis, MD, explore recent advancements in treating urinary stones, focusing on the significance of intrarenal pressure (IRP), its effect on patient outcomes, and methods to decrease elevated IRP.
Use of Targeted Imaging Modalities in Prostate Cancer: Key Challenges and Considerations
Expert insight from David M. Albala, MD, on the evolving landscape of imaging modalities in prostate cancer and how it has impacted treatment pathways.
A Collaborative Approach to the Treatment and Management of Advanced Prostate Cancer
Experts David Morris, MD, FACS, and Benjamin Garmezy, MD, share a dynamic discussion on the respective roles of combination therapy and multidisciplinary care in the current treatment landscape of advanced prostate cancer.
Updates in Precision-Based Approaches to Prostate Cancer Diagnosis and Treatment
Amir H. Lebastchi, MD, investigates advancements in precision-based approaches to prostate cancer diagnosis and therapy, with a focus on the role of MRI and ultrasound fusion technologies.
Clinical Updates on PSMA-PET Imaging for Prostate Cancer
Key opinion leaders discuss the latest PSMA-PET imaging updates for prostate cancer and consider how real-world practice has evolved.
Strategies for Communication and Collaboration in Prostate Cancer Care
Boris Gershman, MD discusses recent advancements in prostate cancer imaging, touching on the clinical application of multiparametric MRI (mpMRI), effective strategies for communication between urologists and radiologists, and how machine learning may shape the future of prostate cancer imaging.
Biomarker Testing for Risk Assessment of Patients Suspected of Having Prostate Cancer
Gerald Andriole, MD discusses pre-biopsy biomarker testing as a risk assessment tool in patients suspected of having prostate cancer, highlighting key advantages and reviewing available options and clinical data, and shares his clinical experience regarding implementation.
Focal Therapy Options for Localized Prostate Cancer
Mark Emberton, BSc, MBBS, FRSC (Urol), MD, FMedSci, provides a historical perspective on treatment options for clinically localized prostate cancer, reviews emerging focal therapy options including HIFU, and discusses how focal therapy has impacted the field.
Addressing Challenges in Urology Practice Management
John J. Kowalczyk, DO, FACOS, shares his experience and perspectives on urology practice management and implementing software tools to improve practice workflows.
Updates on Use of Genomic Testing in Patients with High-Risk, Clinically Localized Prostate Cancer
Stephen J. Freedland, MD, provides an overview of the diagnosis and staging of high-risk, clinically localized prostate cancer and explains how genomic testing helps inform risk stratification and treatment-decision making in his clinical practice.
Implantable Tibial Nerve Stimulation Devices for Treatment of Overactive Bladder
This Uroview features discussion between Dr. Alexandra Rogers and Dr. Scott MacDiarmid about current and emerging treatments for overactive bladder, with a focus on implantable tibial nerve stimulation devices in this space.
Lipidosterolic Extract of Serenoa repens (Saw Palmetto) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Expert perspectives on the use of saw palmetto extracts to manage patients with benign prostatic hyperplasia and lower urinary tract symptoms.
Second-Line Treatment Options in Advanced Prostate Cancer
Robert Dreicer, MD, provides an overview of advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and available and emerging second-line treatment options for mCRPC.
18F-Fluciclovine Versus 68Ga-PSMA-11 Imaging for Prostate Cancer Biochemical Recurrence
Steven Finkelstein, MD, DABR, FACRO, and Louis J. Mazzarelli, MD, react to the article, “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Pernthaler B, et al.
The Role of Androgen Receptor Inhibitors in the Management of Advanced Prostate Cancer
Enteric Hyperoxaluria: Understanding the Disease
Kyle Wood, MD, reviews currently available treatment options for enteric hyperoxaluria and the importance of disease education.
The Role of Liquid Biomarker for Early Detection of Prostate Cancer
Two experts in urology provide a discussion on currently available screening and risk assessment tools in prostate cancer and emphasize the importance of early detection.
Gallium-68 PSMA Targeted PET Imaging in Prostate Cancer: Staging and Outcomes
Analysis of Gallium-68 PSMA 9 (prostate-specific membrane antigen) targeted PET (positron emission tomography) imaging and its impact on staging and prostate cancer.
The Importance of Image Quality in the Urological Workflow
Brad Schwartz, DO, FACS, comments on newer urologic imaging techniques that can reduce exposure to radiation.
Genetic Testing in Prostate Cancer
Specialists in urology discuss the significance of germline testing in prostate cancer.
Treatment Options in Metastatic Castration-Resistant Prostate Cancer: A Year In Review
Dr. Neal Shore reviews treatment options in metastatic castration-resistant prostate cancer available in 2020.
2 Clarke Drive Cranbury, NJ 08512